
- Home
- Companies
- INOVIQ Ltd
- Articles
INOVIQ Ltd articles
Financials have been keeping the ASX in positive territory in today’s session, following improved sentiment for financial stocks after the Bank of Queensland (ASX:BOQ) yesterday announced better-than-expected Net Interest Margin performance. This has bolstered financial stocks and the broader market. At noon, the S&P/ASX 200 is 0.51 per cent or 34.10 points higher at 6681.60.
The SPI fut
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions.
SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market.
INOVIQ Ltd (ASX:IIQ) has successf
- INOVIQ (IIQ) signs a contract research agreement with Nicoya Lifesciences to develop a SubB2M-based test that uses its Alto digital surface plasmon resonance (SPR) platform
- The company believes a SubB2M-based SPR test has the potential to be developed as a multi-cancer detection test that first detects the Neu5Gc cancer signal
- Under the agreement, INOVIQ will pay an agreed cost for the work undertaken and the project is expected to be complete within six mont